The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
Beevers
D G
DG
University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. g.y.h.lip@bham.ac.uk
Lip
G Y
GY
D000368:Aged; D000803:Angiotensin I / Q000096:biosynthesis / Q000187:drug effects*; D000804:Angiotensin II / Q000096:biosynthesis / Q000187:drug effects*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D001713:Biphenyl Compounds / Q000008:administration & dosage; D003922:Diabetes Mellitus, Type 1 / Q000150:complications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D000077405:Irbesartan; D019808:Losartan / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011322:Primary Prevention / Q000379:methods; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D013777:Tetrazoles / Q000008:administration & dosage; D016896:Treatment Outcome
D000806:Angiotensin-Converting Enzyme Inhibitors; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000804:Angiotensin II; D000803:Angiotensin I; D000077405:Irbesartan; D019808:Losartan